29 October 2026
RS Research, a clinical-stage biotechnology company developing smart nanomedicines for targeted oncology therapies, presented detailed results from the completed Phase 1a/1b clinical trial of its lead investigational candidate, RS-0139, at ESMO Congress 2026, held in Madrid, Spain, on 23-27 October.
RS-0139 was developed using Sagitta® Bir, part of RS Research’s proprietary Sagitta® targeted drug delivery platform family. The investigational medicine combines docetaxel with a polymer-based carrier and an integrin-targeting peptide, designed to modify drug delivery and systemic exposure while addressing the longstanding efficacy-toxicity trade-off of conventional chemotherapy.
The first-in-human, multicenter, open-label study evaluated safety, tolerability, pharmacokinetics and exploratory antitumor activity in patients with advanced solid tumors. Following single-dose accelerated titration, which established a maximum tolerated dose of 75 mg/m², the study investigated repeated administration every three weeks at 40 and 60 mg/m².
At the repeat-dose levels of 40-60 mg/m², no neutropenia was observed and no patient required G-CSF support. Pharmacokinetic analyses showed a low released-docetaxel fraction, approximately 4% of total, with no accumulation across cycles. Peripheral neuropathy was the principal safety finding with repeated dosing and will be a key consideration for further development. Exploratory analyses also identified substantial reductions in the tumor-associated marker CA-125 in two patients with gynecological cancers. These early findings provide a foundation for further investigation but do not establish clinical efficacy or comparative safety.
The presentation represents an important step in the clinical translation of Sagitta® as RS Research prepares for international Phase 2 development.
ePoster Title: First-in-human phase Ia/Ib study of RS-0139, an integrin-targeted docetaxel prodrug, in advanced solid tumors
ePoster Number: 1095eP
Date: 23-27 October 2026
Location: IFEMA Madrid, Spain
Clinical Trial: NCT04261413
More information available at publication page
About RS Research
RS Research is a clinical-stage biotechnology company developing smart nanomedicines for targeted therapies through its proprietary Sagitta® drug delivery platform family. With its lead investigational candidate RS-0139 having completed Phase 1, the company is advancing an oncology pipeline supported by integrated drug development expertise, GMP-certified manufacturing capabilities and European Medicines Agency SME status.
For media inquiries: pr@rsresearch.net
For scientific inquiries: medicalinformation@rsresearch.net
